Home
News
Latest News
People Moves
Business Briefs
Newsletters
Features
Features
Reprints
Surveys
Editorial Calendar
Web Exclusives
Issue Archive
Events
MM&M Awards 2012
txt4pharma
MM&M Virtual Summit
Webcasts
Leadership Exchanges
Whitepapers
Directories
Creative Portfolio
Mobile Guide
Interactive Guide
Pharmaceutical Marketers Directory
MM&M Service Directory
Agency Gallery
Direct Marketing Showcase
Medical Education Review
Sales Force Listings
Jobs
About Us
Subscriber Services
Contact Us
Media Information
Editorial Advisory Board
Drug Info
New Drug Dossier
Drug Database
Subscribe
Order Now
Subscriber Services
Newsletters
RSS
|
Login
|
Register
Viewpoint Articles
Do you deserve to be in the right-hand column?
David Paragamian May 01, 2012
Don't think that client marketers and their procurement colleagues don't have the "lists"
FDA wedded to the FTC—for better or for worse
Kurt Mueller April 01, 2012
Without behavioral targeting, it's back to mass marketing using a shotgun approach
When consolidation comes with compromise
Mike Rutstein April 01, 2012
Let clients pick and choose based on best-in-class expertise, as opposed to 'one-stop shopping.'
The very public risks of celebrity endorsements
Pam Garfield March 01, 2012
What happens when a celebrity goes off message, gets a DUI or is photographed eating a hamburger?
Will this be the year Siri becomes board certified?
Nicole Johnson February 01, 2012
Siri's first step towards board certification could be creating a health-specific data engine
It's not the sky that's falling, it's the status quo
Bobbie Montgomery February 01, 2012
The horizon is changing and increasingly challenging. This can be a good and promising thing
To meet changing needs, go to the open source
Mike Rutstein January 01, 2012
To meet new demands, many companies are restructuring—and need agencies who are doing the same. So for healthcare communications companies, the message is clear: adapt or die.
How digital tech can counter Sunshine Act flaws
Lance Hill December 01, 2011
The logistical costs of face-to-face advisory board meetings don't help manufacturers or thought leaders
Sunshine sheds little light on status of reprints
December 01, 2011
It is counterintuitive to place a burden on information that adds value to public health and safety
How Gen X changed the rules for top salespeople
Angela Bakker Lee November 01, 2011
Today, for the top performers from Generation X & Y, it's no longer enough to hunt with the pack
« Previous
Next »
Video Exclusive
Web Exclusives
Five industry experts advise specialty pharma company on digital strategy
April 20, 2012
Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.
MM&M Awards 2011 HIghlights
The Best MM&M Awards Ever!
MAHF Ceremony 2012
Photos from the Medical Advertising Hall of Fame Awards ceremony
Most Popular
Most Emailed
Most Recent
Goodbye Plavix, hello competition
No-see docs are know-nothings when it comes to new drug info, study suggests
Pharmas are from Mars, Payers are from Venus
Study: Young Latinas are key decision makers, prefer English
How CDC's hep.-C testing advice benefits drugmakers now
Xarelto gets no love from FDA panel
Roundtable outlines path for publisher, pharma credibility
Did FDA's Vytorin warning negatively impact health outcomes?
PhRMA's Washington wish list
E-prescriptions boost adherence data
Study: Young Latinas are key decision makers, prefer English
No-see docs are know-nothings when it comes to new drug info, study suggests
Pharmas are from Mars, Payers are from Venus
E-prescriptions boost adherence data
How CDC's hep.-C testing advice benefits drugmakers now
Goodbye Plavix, hello competition
Xarelto gets no love from FDA panel
Roundtable outlines path for publisher, pharma credibility
PhRMA's Washington wish list
Did FDA's Vytorin warning negatively impact health outcomes?
POM aims arch ads at FTC tormentors
Xarelto gets no love from FDA panel
Did FDA's Vytorin warning negatively impact health outcomes?
Roundtable outlines path for publisher, pharma credibility
No-see docs are know-nothings when it comes to new drug info, study suggests
E-prescriptions boost adherence data
How CDC's hep.-C testing advice benefits drugmakers now
PhRMA's Washington wish list
Study: Young Latinas are key decision makers, prefer English
Pharmas are from Mars, Payers are from Venus
Popular Topics
Acquisition
Adherence
Advertising
App
Celebrity
Clinical Trial
Co-Marketing
Diabetes
Diagnostics
Digital
Direct To Consumer (DTC)
Disease Awareness
Downsize
DTC
Education & Awareness
FDA
Food
FTC
Government
Guidance
Health Plans
HMOs
Hospitals
Marketing Research
Sales Force